Geneos Wealth Management Inc. Supernus Pharmaceuticals, Inc. Transaction History
Geneos Wealth Management Inc.
- $3.92 Billion
- Q2 2025
A detailed history of Geneos Wealth Management Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Geneos Wealth Management Inc. holds 108 shares of SUPN stock, worth $5,321. This represents 0.0% of its overall portfolio holdings.
Number of Shares
108
Previous 69
56.52%
Holding current value
$5,321
Previous $2,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding SUPN
# of Institutions
313Shares Held
61.5MCall Options Held
18.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$512 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$306 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$237 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$149 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.76MShares$136 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.64B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...